Superstring Capital Management’s Immunovant IMVT Stock Holding History

Superstring Capital Management’s Portfolio IMVT Stock Details IMVT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$8.03M	Sell	208,368 -149,238	-42%	-$4.55M	5.07%	9
2026 Q1	$8.88M	Buy	357,606 +68,929	+24%	+$1.78M	6.35%	2
2025 Q4	$7.34M	Sell	288,677 -52,671	-15%	-$1.17M	3.93%	7
2025 Q3	$5.5M	Buy	+341,348	New	+$5.53M	5.42%	5
2024 Q4	–	Sell	-12,447	Closed	-$355K	–	44
2024 Q3	$355K	Buy	+12,447	New	+$367K	0.31%	25
2024 Q1	–	Sell	-203,592	Closed	-$8.58M	–	39
2023 Q4	$8.58M	Buy	+203,592	New	+$7.49M	6.12%	7

Other funds holding IMVT

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

TCM

TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Superstring Capital Management's IMVT Position: Q2 2026 in Review

Superstring Capital Management reduced its Immunovant (IMVT) stake by 42% in Q2 2026, selling an estimated $4.55M and leaving 208,368 shares worth $8.03M. The position accounts for 5.07% of the portfolio, ranked #9.

Superstring Capital Management first reported a position in IMVT in Q4 2023 and has held it in 6 quarters since. The position peaked at $8.88M in Q1 2026. 227 funds tracked by Wall St. Rank hold IMVT as of Q2 2026.

Superstring Capital Management held 208,368 shares of Immunovant worth $8.03M as of Q2 2026.
Superstring Capital Management sold 149,238 Immunovant shares in Q2 2026, an estimated $4.55M.
Immunovant made up 5.07% of Superstring Capital Management's portfolio in Q2 2026, its #9 holding.
Superstring Capital Management first reported a position in Immunovant in Q4 2023 and has held it in 6 quarters since.
Superstring Capital Management's Immunovant position peaked at $8.88M in Q1 2026.
227 funds tracked by Wall St. Rank held Immunovant as of Q2 2026.

Based on Superstring Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.